Torsten Kucharzik1, Sibylle Koletzko, Klaus Kannengiesser, Axel Dignass. 1. Department of General Internal Medicine and Gastroenterology, University Teaching Hospital Lüneburg; Dr. von Hauner Children's Hospital, LMU Klinikum, University of Munich; Department of Pediatrics, Gastroenterology and Nutrition, School of Medicine Collegium Medicum University of Warmia and Mazury, Olsztyn, Poland; Department of Pediatric Gastroenterology, LMU Klinikum, University of Munich; Medical Clinic I, Agaplesion Markus Krankenhaus, Frankfurt/Main.
Abstract
BACKGROUND: Ulcerative colitis is a chronic inflammatory bowel disease with an estimated 150 000 patients in Germany alone. METHODS: This review is based on publications about current diagnostic and therapeutic strategies for ulcerative colitis that were retrieved by a selective search in PubMed, and on current guidelines. RESULTS: The primary goal of treatment is endoscopically confirmed healing of the mucosa. Mesalamine, in various forms of administration, remains the standard treatment for uncomplicated ulcerative colitis. Its superiority over placebo has been confirmed in meta-analyses of randomized, controlled trials. Glucocorticoids are highly effective in the acute treatment of ulcerative colitis, but they should only be used over the short term, because of their marked side effects. Further drugs are available to treat patients with a more complicated disease course of ulcerative colitis, including azathioprine, biological agents, JAK inhibitors (among them TNF antibodies, biosimilars, ustekinumab, vedolizumab, and tofacitinib), and calcineurin inhibitors. Proctocolectomy should be considered in refractory cases, or in the presence of high-grade epithelial dysplasia. Ulcerative colitis beginning in childhood or adolescence is often characterized by rapid progression and frequent comorbidities that make its treatment a special challenge. CONCLUSION: A wide variety of drugs are now available for the treatment of ulcerative colitis, enabling the individualized choice of the best treatment for each patient. Regular surveillance colonoscopies to rule out colon carcinoma should be scheduled at intervals that depend on risk stratification.
BACKGROUND:Ulcerative colitis is a chronic inflammatory bowel disease with an estimated 150 000 patients in Germany alone. METHODS: This review is based on publications about current diagnostic and therapeutic strategies for ulcerative colitis that were retrieved by a selective search in PubMed, and on current guidelines. RESULTS: The primary goal of treatment is endoscopically confirmed healing of the mucosa. Mesalamine, in various forms of administration, remains the standard treatment for uncomplicated ulcerative colitis. Its superiority over placebo has been confirmed in meta-analyses of randomized, controlled trials. Glucocorticoids are highly effective in the acute treatment of ulcerative colitis, but they should only be used over the short term, because of their marked side effects. Further drugs are available to treat patients with a more complicated disease course of ulcerative colitis, including azathioprine, biological agents, JAK inhibitors (among them TNF antibodies, biosimilars, ustekinumab, vedolizumab, and tofacitinib), and calcineurin inhibitors. Proctocolectomy should be considered in refractory cases, or in the presence of high-grade epithelial dysplasia. Ulcerative colitis beginning in childhood or adolescence is often characterized by rapid progression and frequent comorbidities that make its treatment a special challenge. CONCLUSION: A wide variety of drugs are now available for the treatment of ulcerative colitis, enabling the individualized choice of the best treatment for each patient. Regular surveillance colonoscopies to rule out colon carcinoma should be scheduled at intervals that depend on risk stratification.
Authors: Lotte C Dinesen; Alissa J Walsh; Marijana Nedeljkovic Protic; Graham Heap; Fraser Cummings; Bryan F Warren; Bruce George; Neil J M Mortensen; Simon P L Travis Journal: J Crohns Colitis Date: 2010-02-19 Impact factor: 9.071
Authors: Fernando Gomollón; Axel Dignass; Vito Annese; Herbert Tilg; Gert Van Assche; James O Lindsay; Laurent Peyrin-Biroulet; Garret J Cullen; Marco Daperno; Torsten Kucharzik; Florian Rieder; Sven Almer; Alessandro Armuzzi; Marcus Harbord; Jost Langhorst; Miquel Sans; Yehuda Chowers; Gionata Fiorino; Pascal Juillerat; Gerassimos J Mantzaris; Fernando Rizzello; Stephan Vavricka; Paolo Gionchetti Journal: J Crohns Colitis Date: 2016-09-22 Impact factor: 9.071
Authors: J Burisch; N Pedersen; S Čuković-Čavka; M Brinar; I Kaimakliotis; D Duricova; O Shonová; I Vind; S Avnstrøm; N Thorsgaard; V Andersen; S Krabbe; J F Dahlerup; R Salupere; K R Nielsen; J Olsen; P Manninen; P Collin; E V Tsianos; K H Katsanos; K Ladefoged; L Lakatos; E Björnsson; G Ragnarsson; Y Bailey; S Odes; D Schwartz; M Martinato; G Lupinacci; M Milla; A De Padova; R D'Incà; M Beltrami; L Kupcinskas; G Kiudelis; S Turcan; O Tighineanu; I Mihu; F Magro; L F Barros; A Goldis; D Lazar; E Belousova; I Nikulina; V Hernandez; D Martinez-Ares; S Almer; Y Zhulina; J Halfvarson; N Arebi; S Sebastian; P L Lakatos; E Langholz; P Munkholm Journal: Gut Date: 2013-04-20 Impact factor: 23.059
Authors: Johan Van Limbergen; Richard K Russell; Hazel E Drummond; Marian C Aldhous; Nicola K Round; Elaine R Nimmo; Linda Smith; Peter M Gillett; Paraic McGrogan; Lawrence T Weaver; W Michael Bisset; Gamal Mahdi; Ian D Arnott; Jack Satsangi; David C Wilson Journal: Gastroenterology Date: 2008-07-03 Impact factor: 22.682
Authors: John G Williams; M Fasih Alam; Laith Alrubaiy; Ian Arnott; Clare Clement; David Cohen; John N Gordon; A Barney Hawthorne; Mike Hilton; Hayley A Hutchings; Aida U Jawhari; Mirella Longo; John Mansfield; Jayne M Morgan; Frances Rapport; Anne C Seagrove; Shaji Sebastian; Ian Shaw; Simon P L Travis; Alan Watkins Journal: Lancet Gastroenterol Hepatol Date: 2016-09
Authors: Tom Øresland; Willem A Bemelman; Gianluca M Sampietro; Antonino Spinelli; Alastair Windsor; Marc Ferrante; Philippe Marteau; Oded Zmora; Paulo Gustavo Kotze; Eloy Espin-Basany; Emmanuel Tiret; Giuseppe Sica; Yves Panis; Arne E Faerden; Livia Biancone; Imerio Angriman; Zuzana Serclova; Anthony de Buck van Overstraeten; Paolo Gionchetti; Laurents Stassen; Janindra Warusavitarne; Michel Adamina; Axel Dignass; Rami Eliakim; Fernando Magro; André D'Hoore Journal: J Crohns Colitis Date: 2015-01 Impact factor: 10.020